Merck & Co
Open
$111.94
Prev. Close
$112.04
High
$111.94
Low
$111.84
Market Snapshot
$275.38B
15.1
6.76
$64.17B
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
emptyResult
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Recently from Cashu
Merck & Co. Initiates Phase 2b/3 Trial for Eye Drug MK-8748 Targeting Vision Loss
Merck & Co. announces a pivotal advancement in ophthalmology with the initiation of a Phase 2b/3 clinical trial for MK-8748, its investigational eye drug aimed at treating neovascular age-related macu…
Merck & Co Partners with Infinimmune to Enhance Therapeutic Development and Innovation
Merck & Co Expands Therapeutic Reach Through Strategic Partnership with Infinimmune Merck & Co continues to strengthen its position in the pharmaceutical industry by entering into a significant partne…
Merck & Co Partners with Infinimmune to Enhance Therapeutics and Address Medical Needs
Merck & Co: Pioneering Therapeutics Through Strategic Collaboration Merck & Co. establishes a promising partnership with Infinimmune, emphasizing its commitment to advancing therapeutic solutions in t…
Merck Introduces Employee Pet Care Benefits Amid Changing Workplace Dynamics
Merck Embraces Employee-Centric Care: A Shift Toward Pet Care Benefits In a notable shift reflecting changing workplace dynamics, Merck & Co embraces innovative employee benefits that cater to emergin…